Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Scoping Review of Exercise Oncology in the Primary Brain Tumor Patient-Caregiver Dyad.

Current oncology (Toronto, Ont.)·2026
Same author

STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025
Same author

Phase Ib/II Study of Pamiparib Plus Radiation Therapy and/or Temozolomide in Adult Patients with Treatment-Naïve or Recurrent/Refractory Glioblastoma.

Current oncology (Toronto, Ont.)·2025
Same author

Novel radiotherapy target definition using AI-driven predictions of glioblastoma recurrence from metabolic and diffusion MRI.

NPJ digital medicine·2025
Same author

IL-6 underlies microenvironment immunosuppression and resistance to therapy in glioblastoma.

bioRxiv : the preprint server for biology·2025
Same author

A phase I study of convection-enhanced delivery (CED) of liposomal-irinotecan using real-time magnetic resonance imaging in patients with recurrent high-grade glioma.

Journal of neuro-oncology·2025

Related Experiment Video

Updated: Jun 18, 2026

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
11:15

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

Immunostimulants for malignant gliomas.

Nicholas Butowski1

  • 1Department of Neurological Surgery, University of California San Francisco, 400 Parnassus Avenue, A808, San Francisco, CA 94143, USA. butowski@neurosurg.ucsf.edu

Neurosurgery Clinics of North America
|December 1, 2009
PubMed
Summary
This summary is machine-generated.

Immunotherapy for gliomas is evolving. Newer strategies focus on direct immune cell stimulation, potentially improving treatment outcomes when combined.

More Related Videos

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells
12:52

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Published on: November 28, 2015

Related Experiment Videos

Last Updated: Jun 18, 2026

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
11:15

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells
12:52

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Published on: November 28, 2015

Area of Science:

  • Oncology
  • Immunology
  • Biotechnology

Background:

  • Gliomas are challenging brain tumors with limited treatment options.
  • Traditional immunotherapy for gliomas has involved non-specific cytokine administration.
  • Recent advancements aim for more targeted and natural immune system activation.

Purpose of the Study:

  • To review current and emerging immunostimulant strategies for glioma treatment.
  • To highlight the shift towards direct immune cell modulation.
  • To explore the potential of combination immunotherapies.

Main Methods:

  • Review of literature on glioma immunotherapy.
  • Analysis of cytokine delivery methods (systemic, cell-based, gene transfer).
  • Examination of pattern recognition receptor-targeted agents.

Main Results:

  • Early cytokine therapies were non-specific.
  • Genetically modified cells and in vivo gene transfer offer localized cytokine delivery.
  • Newer agents target antigen-presenting and effector cells directly.
  • Combining multiple immunotherapy approaches shows promise.

Conclusions:

  • Immunotherapy for gliomas has progressed from non-specific to targeted strategies.
  • Direct stimulation of immune cells via pattern recognition receptors is a key focus.
  • Combination immunotherapy holds potential for enhanced clinical efficacy in glioma treatment.